Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

In what researchers are calling an important scientific advance, a team in the US has shown through animal experiments that Alzheimer’s disease may be reversible, overturning a belief that has shaped medical thinking for more than 100 years. For generations, the neurodegenerative condition was considered permanent and progressive. The findings, published in Cell Reports Medicine, are based on multiple preclinical mouse models as well as examinations of human Alzheimer’s brain tissue.

The study found that preserving a healthy balance of NAD, a molecule central to cellular energy production, could both prevent and reverse Alzheimer’s-related damage. NAD plays a key role in brain function and is now seen as a major contributor to the disease process. Researchers also observed that NAD levels drop much more sharply in the brains of people with Alzheimer’s, a pattern that was mirrored in mouse models of the condition.

Don't Miss: Taking Tramadol? Scientists Warn It May Cause More Harm Than Relief

Alzheimer’s Disease Can Be Reversed, New Study Shows

“We were extremely encouraged by what we observed,” said Andrew A. Pieper, the study’s senior author and Director of the Brain Health Medicines Center at the Harrington Discovery Institute, University Hospitals, as per Sciencedirect. “By restoring the brain’s energy balance, we saw both structural and functional recovery in mice with advanced Alzheimer’s.”

Pieper noted that the effect appeared consistently across two very different mouse models, each driven by separate genetic mechanisms linked to Alzheimer’s in humans. “Seeing recovery in models caused by distinct genetic pathways strengthens the case that restoring NAD balance in the brain could have real therapeutic potential for patients,” he said.

For the study, researchers examined mice engineered to carry genetic mutations known to cause Alzheimer’s disease in people. One group of mice carried multiple human mutations affecting amyloid processing, while the second group carried a human mutation in the tau protein.

After confirming that brain NAD levels dropped sharply in both human Alzheimer’s tissue and mouse models, the team tested whether stopping this decline before symptoms appeared could prevent disease, and whether restoring NAD levels after the disease had progressed could reverse it. To do this, they used a well-studied drug called P7C3-A20 to restore NAD balance in the brain.

The results were striking. Not only did maintaining NAD levels prevent Alzheimer’s from developing in mice, but starting treatment later, after the disease was already advanced, allowed the brain to repair the main pathological damage caused by the genetic mutations. In both mouse models, cognitive abilities were fully restored.

What Is NAD In Alzheimer’s?

In Alzheimer’s disease, NAD, short for nicotinamide adenine dinucleotide, is an essential coenzyme whose levels naturally decline with age. This decline disrupts energy production, mitochondrial health, DNA repair, and the ability of neurons to withstand stress. Research suggests that increasing NAD levels, often through precursors such as nicotinamide riboside, may reverse Alzheimer’s-related damage, improve memory, and correct abnormal RNA processing in animal models. Because of this, NAD has become a major area of focus for developing new Alzheimer’s therapies, according to the National Institutes of Health.

Why NAD Is Important In Alzheimer’s

• Energy and Mitochondria: NAD is necessary for producing ATP, the cell’s main energy source, and for keeping mitochondria functioning properly, both of which are critical for healthy brain cells.
• Cellular Stress: NAD supports neurons in responding to and surviving stress. When NAD levels fall in Alzheimer’s, these protective mechanisms weaken.
• DNA Repair: NAD is involved in repairing DNA damage, which increases as amyloid-beta accumulates in the brain. Low NAD levels interfere with this repair process.
• RNA Splicing: Emerging research shows that NAD may help correct faulty RNA splicing events linked to Alzheimer’s. This process may involve a protein called EVA1C and could contribute to improved memory and better clearance of harmful proteins.

Next Steps Toward Human Trials

The findings also pave the way for further research and eventual testing in people. The technology behind the treatment is currently being developed for commercial use by Glengary Brain Health, a Cleveland-based company co-founded by Dr. Pieper.

“This recovery-based treatment approach now needs to be tested in carefully designed clinical trials to see if the benefits seen in animals can be replicated in humans,” Pieper said.

He added that future laboratory work will focus on identifying which components of brain energy balance matter most for recovery, exploring additional strategies that could complement this approach, and determining whether similar methods could work for other long-term, age-related neurodegenerative diseases as well.

Adenovirus, or what some people are calling the mystery disease is going to be the next worry in the UK, after superflu had already grappled the healthcare system. Along with H3N2 and its variant superclade K, people are now worrying about this mystery disease.

Adenovirus is highly contagious and causes mild cold or flu-like symptoms, though severe cases could lead to stomach flu and vomiting. Many describe this virus as 'heartier' than others. The reason is that the virus can survive longer on surfaces and even resist the common disinfectants used. This is what makes it highly transmissible.

Is There Any Treatment For Adenovirus?

As of now, there is no treatment for adenovirus, it could however be managed and monitored. What helps is regular handwashing and thorough cleaning of surfaces.

The good news is that cases of adenovirus are actually dropping in the UK, as confirmed lab reports. The cases last week were 1.2 per cent, whereas the week prior, it was at 1.7 per cent, as also reported by the Independent.

What Are The Symptoms Of Adenovirus?

While a lot of the symptoms mimics of those in flu or COVID, including shortness of breath, a sore throat and or a runny nose. However, there are certain unique symptoms of adenovirus that include:

• Diarrhea
• Pink Eye or conjunctivitis
• Ear infection or otitis media
• Swollen lymph nodes
• Pneumonia
• Stomach pain
• Nausea
• Vomiting

Other rare symptoms could also include impact on your bladder or nervous system. As viruses in your bladder can also cause urinary tract infections, and the same virus in your nervous system can cause condition that can affect your brain. These conditions also include encephalitis and meningitis.

The symptoms usually start to subside within two days, however, if the symptoms stay even after three days without any relief, it might be a red flag. The best thing to do during such a situation is to go consult your GP.

Also Read: Unique Symptoms Of Mysterious Adenovirus And How Long Infection Now Last

Is Adenovirus Spreading Faster Than Flu and Covid?

Experts have noted that due to its ability to stay longer in the environment and being highly transmissible, it is in fact, spreading faster than flu and COVID. Eric Sachinwalla, Jefferson Health's medical director said that this virus is still unfamiliar and thus not much can actually be done to treat adenovirus. Speaking to PhillyMad, he said, "It is pretty contagious because it is heartier than other viruses - soap and water, or everyday disinfectant, won't kill it, so it tends to live in the environment longer."

What Are The Ways To Stay Safe From Adenovirus?

Since adenovirus spreads through close contact and is resistant to many everyday disinfectants, hygiene remains the key. The best way to stay safe is by avoiding close contact, especially with those who are unwell. You may also keep an eye on your symptoms, including your body temperature and take steps to prevent the virus from spreading by taking precautions, as well as getting the flu jab.

The World Health Organization (WHO) on December 24 prequalified two rapid antigen diagnostic tests (Ag-RDTs) for SARS-CoV-2. This virus is known to have caused COVID-19. As per the WHO, these two tests are called SD Biosensor STANDARD Q COVID-19 Ag Test and the ACON Biotech Flowflex SARS-CoV-2 Antigen Rapid Test (Self-Testing).

At first these tests got temporary emergency approval from the WHO during the pandemic. This was done so the countries could start using them quickly even though long-term data was limited. This emergency approval helped the tests reach over 100 countries when they were urgently needed.

What Has Changed Now?

The WHO has now given these tests full prequalification, which means it has a stronger and long-term approval. This means that the WHO has thoroughly checked and confirmed that the tests consistently meet global standards for quality, safety, and accuracy.

Why Does This Matter?

• The tests can now be officially bought and used by global organizations and governments
• They can be included in bulk purchasing to lower prices and increase supply
• This makes reliable COVID-19 testing more affordable and accessible, especially in low-and middle-income countries

COVID-19 Is Far From Being Over

Even though WHO officially ended COVID-19 emergency phase over two years ago, the virus is still circulating globally. In fact, this year, we have seen variants of COVID-19 circulating around, causing the most unique symptoms, including razor-blade like throat. Variants like JN.1, Stratus, Nimbus, LP8.1, and BA.3.2 were all that we saw in 2025.

While the good news is that infection levels are relatively stable, but the virus has not completely disappeared and testing is still necessary, especially in poorer countries.

Many low-income countries do not have easy access to labs or expensive PCR testing. So there is still a need for a strong, but cheaper and reliable way to detect COVID-19, and these tests may as well do that.

Why Rapid Antigen Test Matters

• Give results in 15–30 minutes
• Cost less than PCR tests
• Don’t require labs or specialized equipment
• This means they can be used in small clinics, community centers, mobile vans, or remote areas, where lab testing isn’t practical.

However, it is important to note that rapid antigen tests are not replacement for PCR tests. They simply complement the PCR tests by allowing faster, on-the-spot decisions, especially when the lab capacity is limited.

What Makes It Essential Today?

Rapid antigen tests could help with spotting and stopping local outbreaks quickly, protecting high-risk people and healthcare workers, and staying prepared for future respiratory pandemics.

The WHO is also pushing for decentralized, quality-checked testing as part of universal healthcare and global health security, so countries aren’t caught unprepared when the next outbreak happens.

When Is It A Right Time To Get Yourself Checked For COVID-19?

If you notice these following symptoms as noted by the Centers for Disease Control and Prevention (CDC), it is best that you get yourself a COVID-19 test:

• Fever or chills
• Cough
• Shortness of breath or difficulty breathing
• Sore throat
• Congestion or runny nose
• New loss of taste or smell
• Fatigue
• Muscle or body aches